Lonza Group AG (VIE:LONN)
Austria · Delayed Price · Currency is EUR | Market Cap | 36.42B -5.2% |
| Revenue (ttm) | 7.01B -1.6% |
| Net Income | -295.37M |
| EPS | -4.22 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 26.21 |
| Dividend | 4.27 (0.81%) |
| Ex-Dividend Date | May 13, 2025 |
| Volume | n/a |
| Average Volume | n/a |
| Open | 525.40 |
| Previous Close | 525.40 |
| Day's Range | 525.40 - 533.20 |
| 52-Week Range | 499.60 - 633.60 |
| Beta | n/a |
| RSI | 39.40 |
| Earnings Date | Apr 1, 2026 |
About Lonza Group AG
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanc... [Read more]
News
Simulations Plus (SLP) Partners with FDA and Lonza for Drug Performance Research
Simulations Plus (SLP) Partners with FDA and Lonza for Drug Performance Research
Lonza Group AG Transcript: Investor update (Q&A)
A major portfolio transformation is complete with the divestment of 60% of CHI, focusing the business as a pure-play CDMO. Proceeds of at least CHF 3 billion will fund organic growth, bolt-on M&A, and a CHF 500 million share buyback, with 2026 guidance unchanged.
Lonza Group AG Transcript: Investor update
A major portfolio transformation is completed with the divestment of 60% of CHI, enabling a pure-play CDMO focus. Proceeds of at least CHF 3 billion will fund organic growth, acquisitions, and a CHF 500 million share buyback, while the 2026 outlook remains robust.
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG
DALLAS & NEW YORK & LONDON & TOKYO--(BUSINESS WIRE)--Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the ...
Lonza Group AG Earnings Call Transcript: H2 2025
Delivered CHF 6.5 billion in sales (+21.7% constant currency), with core EBITDA margin up to 31.6% and free cash flow nearly doubling. Outlook for 2026 is 11%-12% sales growth and margin above 32%, supported by strong segment performance and disciplined capital allocation.
Lonza Group AG Transcript: 44th Annual J.P. Morgan Healthcare Conference
A clear strategy and robust financial model underpin strong growth, with major investments in global capacity and technology. The Vacaville acquisition strengthens U.S. presence, while ongoing regionalization and high customer retention support long-term value creation.
Lonza Group AG Earnings Call Transcript: Q3 2025
Strong Q3 performance and robust contracting support confirmation of 2025 outlook, with CDMO sales growth of 20–21% and margin of 30–31%. Vacaville and CHI businesses are progressing as planned, and growth projects remain on track despite FX and funding headwinds.
Lonza Group AG Earnings Call Transcript: H1 2025
Delivered strong H1 2025 results with 19% CER sales growth and upgraded full-year CDMO guidance to 20%-21% sales growth and 30%-31% core EBITDA margin. Integrated Biologics and Advanced Synthesis drove performance, while CHI recovery and major CapEx projects progressed.
Lonza Group AG Earnings Call Transcript: Q1 2025
Strong Q1 2025 performance supports a confirmed outlook for nearly 20% sales growth and a core EBITDA margin near 30%. Segment momentum is robust, with high asset utilization and ongoing growth projects, while risk from tariffs and FX is mitigated by global footprint and hedging.
Lonza Group AG Earnings Call Transcript: H2 2024
2024 results showed stable revenues at CHF 6.6 billion, with strong CDMO growth offsetting CHI declines. 2025 guidance anticipates CDMO revenue growth near 20% and margin expansion, supported by new capacity and the Vacaville acquisition.
Lonza Group AG Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025
A new unified vision and strategy were outlined, focusing on becoming a pure-play CDMO and leveraging the Lonza Engine for growth. The company is exiting the CHI business, investing in global capacity, and targeting low-teens organic growth, with strong execution and positive market outlook.
Lonza Group AG Transcript: Investor Update
A new unified strategy and organizational structure were unveiled, focusing on the 'Lonza Engine' to drive above-market growth, operational excellence, and value creation. Guidance was updated to a rolling, organic growth model, with low-teens sales growth and margins approaching 30%, while the CHI business will be divested.
Lonza Group AG Earnings Call Transcript: Q3 2024
Q3 performance is on track with full-year guidance, with strong momentum in Biologics, Small Molecules, and Cell and Gene divisions. CapEx will be slightly below guidance, and key growth projects are progressing, while Capsules and BioScience divisions are expected to recover in 2025.
Lonza Group AG Earnings Call Transcript: H1 2024
H1 2024 saw 1.8% sales growth and a 29.2% core EBITDA margin, with strong CDMO performance offset by CHI headwinds. The Vacaville acquisition will double mammalian capacity, and full-year guidance for flat sales growth and high-20s EBITDA margin is reaffirmed.
LZAGY, DSDVY: Investment Opportunities Outside of the U.S.
U.S. equity markets have benefitted from a perceived quality advantage over Europe, though it's uncertain when outperformance will end, notes Bryan Lee. He discusses finding investment opportunities o...
Lonza Group AG Earnings Call Transcript: Q1 2024
Lonza Group AG Transcript: Trading Update
Lonza Group AG Transcript: Investor Update
Lonza Group AG Earnings Call Transcript: H2 2023
Lonza chairman to step down, drugmaker confirms targets, shares soar
Lonza said on Friday Chairman Albert Baehny will step down in May after six years in the job, in a second senior management reshuffle in recent months as the Swiss contract drug manufacturer grapples ...
Lonza Group AG Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024
Lonza Group AG Transcript: CMD 2023
Lonza CEO departure prompts concern over earnings prospects
Contract drug manufacturer Lonza said on Monday Chief Executive Pierre-Alain Ruffieux will leave the Swiss company by mutual agreement at the end of the month, weighing on investor confidence about th...